A share price of Prime Medicine Inc [PRME] is currently trading at $1.33, up 11.76%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PRME shares have gain 4.72% over the last week, with a monthly amount drifted -20.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Prime Medicine Inc [NASDAQ: PRME] stock has seen the most recent analyst activity on May 27, 2025, when Citigroup downgraded its rating to a Neutral but kept the price target unchanged to $1.50 for it. Previously, JP Morgan downgraded its rating to Neutral on May 20, 2025. On May 20, 2025, downgrade downgraded it’s rating to Neutral. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $10 on December 10, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $10 as its price target on May 20, 2024. Citigroup upgraded its rating to Buy for this stock on May 16, 2024, but kept the price target unchanged to $10. In a note dated April 22, 2024, Chardan Capital Markets initiated an Buy rating and provided a target price of $17 on this stock.
Prime Medicine Inc experienced fluctuations in its stock price throughout the past year between $1.11 and $8.14. Currently, Wall Street analysts expect the stock to reach $17.25 within the next 12 months. Prime Medicine Inc [NASDAQ: PRME] shares were valued at $1.33 at the most recent close of the market. An investor can expect a potential return of 1196.99% based on the average PRME price forecast.
Analyzing the PRME fundamentals
Trailing Twelve Months sales for Prime Medicine Inc [NASDAQ:PRME] were 3.85M which represents 146.02% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -4.86%, and Net Profit Margin reading is -4.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -1.25 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2370 points at the first support level, and at 1.1440 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3860, and for the 2nd resistance point, it is at 1.4420.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Prime Medicine Inc [NASDAQ:PRME] is 4.78. Further, the Quick Ratio stands at 4.78, while the Cash Ratio is 2.68. Considering the valuation of this stock, the price to sales ratio is 45.36, the price to book ratio is 1.63.
Transactions by insiders
Recent insider trading involved Brudnick Richard, Chief Business Officer, that happened on May 20 ’25 when 20000.0 shares were purchased. Chief Technical Officer, LEE ANN L. completed a deal on May 21 ’25 to buy 100000.0 shares. Meanwhile, Chief Executive Officer Reine Allan bought 0.12 million shares on May 21 ’25.
